This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bristol-Myers Squibb To Present Data On Rheumatoid Arthritis Assets At American College Of Rheumatology (ACR) 2013 Annual Meeting

Bristol-Myers Squibb Company (NYSE: BMY) announced today that 20 abstracts have been accepted for presentation at the 2013 annual meeting of the American College of Rheumatology (ACR) taking place from October 25-30 in San Diego, CA. The breadth of data underscores the Company’s continued commitment to develop medicines that address the unmet medical needs of patients suffering from rheumatic and other immune-mediated diseases.

Key presentations include:
  • The first presentation of efficacy and safety results from a Phase IIb study of subcutaneous (SC) clazakizumab, an investigational anti-IL-6 monoclonal antibody, in adults with moderate-to-severe rheumatoid arthritis (RA) and an inadequate response to methotrexate. Bristol-Myers Squibb has exclusive worldwide rights to develop and commercialize clazakizumab for all indications outside of cancer under a collaboration agreement with its discoverer, Alder Biopharmaceuticals.
  • Results from the two-year AMPLE trial of Orencia ® SC (abatacept) and Humira ® (adalimumab) in biologic-naive RA patients, including efficacy, safety and patient-reported outcomes data.
  • More than 10 health economics and outcomes research presentations that add to the collective understanding of real-world use of RA medications and the costs associated with treatment.

“Bristol-Myers Squibb will continue its long standing commitment to immunoscience research and to a strong culture of innovation to help further advancements in the treatment of immune-mediated diseases like RA,” said Michael Giordano, senior vice president, Head of Development, Oncology and Immunology, Bristol-Myers Squibb. “The data and findings we are presenting at the ACR annual meeting demonstrate our commitment to pre-clinical, clinical, and real world and health outcome research to help patients.”

The complete list of Bristol-Myers Squibb presentations is below. Abstracts can be accessed on the ACR website at
Title   Date/Time
A Phase IIb Study Of The Efficacy and Safety Of Subcutaneous Clazakizumab (anti-IL-6 monoclonal antibody) With Or Without Methotrexate In Adults With Moderate-To-Severe Active Rheumatoid Arthritis and An Inadequate Response To Methotrexate Oral Presentation

October 28

2:30 - 4 pm
Anti-IL-6 Antibody Clazakizumab Is More Potent Than Tocilizumab In Blocking In Vitro and Ex Vivo IL-6-Induced Functions October 29
ORENCIA (Abatacept)  
Head-To-Head Comparison of Subcutaneous Abatacept Versus Adalimumab on Background Methotrexate in RA: Two Year Results from the AMPLE Study October 29
2-Year Results from the AMPLE (Abatacept versus Adalimumab Comparison in Biologic-Naïve RA Patients with Background Methotrexate) Trial: Changes in Patient-Reported Outcomes in Response to Subcutaneous Abatacept or Adalimumab in Rheumatoid Arthritis October 27
Effects of SC Abatacept or Adalimumab on Remission and Associated Changes in Physical Function and Radiographic Outcomes: Two Year Results from the AMPLE Trial October 27
Abatacept or anti-TNF monoclonal antibodies: Efficacy and safety comparisons October 29
Antibody response to pneumococcal and influenza vaccination in patients with RA receiving subcutaneous abatacept October 27
Adherence to the Recommended Dosing Regimen of Abatacept in the Real-world Setting in the ACTION Study: Is There a Dose-creep in Overweight Patients? October 28
Gene expression in whole blood predicts the abatacept-methotrexate combination responsiveness in rheumatoid arthritis: preliminary results October 29
Abatacept is highly effective at inhibiting T cell priming and induces a unique transcriptional profile in CD4+ T cells October 27
Pilot Study of Abatacept in Patients with Refractory Autoimmune Chronic Urticaria October 29
Musculoskeletal Hospital Admissions Among Patients Treated For Rheumatoid Arthritis Between 1999 and 2010 Compared With The General Population In The Netherlands October 27
Evaluation Of Hospitalizations and Costs In Patients With Rheumatoid Arthritis In United States Medicare Population October 28
Analysis Of Non-Steroidal Anti-Inflammatory Drug Burden Among Rheumatoid Arthritis Patients Using The Dougados Algorithm October 27
Biologic Switching Rates among Patients with Rheumatoid Arthritis in Medicare October 29
Rates of Switching and Healthcare Costs Associated with Switching Biologic Disease-modifying Antirheumatic Drugs in a Commercial Population: Evidence from Real-world Observational Studies October 28
Outcomes of patients with rheumatoid arthritis and comorbid hyperlipidaemia October 27
Prevalence of Systemic Lupus Erythematosus and Lupus Nephritis in the United States: Analysis of Commercial and Public Insurance Billing Data October 28
Coronary endothelial dysfunction directly measured by N13 Positron Emission Tomography (PET) is detected in established Rheumatoid Arthritis (RA), but not early RA October 27
Assessing Validity Of Low Field Magnetic Resonance Imaging (MRI) for Joint Inflammation and Damage In Wrist/Hand Rheumatoid Arthritis (RA) - A Systematic Literature Review (SLR) October 29

About Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a systemic, chronic, autoimmune disease characterized by inflammation in the lining of joints (or synovium), causing joint damage with chronic pain, stiffness, swelling and fatigue. RA causes limited range of motion and decreased joint function. The condition is more common in women than in men, who account for 75% of patients diagnosed with RA.

About Orencia ® (abatacept)

Orencia subcutaneous (SC) injection and intravenous (IV) infusion are indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Orencia may be used as monotherapy or concomitantly with disease-modifying antirheumatic drugs (DMARDs) other than tumor necrosis factor (TNF) antagonists.

Orencia IV is indicated for reducing signs and symptoms in pediatric patients 6 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis. Orencia IV may be used as monotherapy or concomitantly with methotrexate (MTX). Orencia SC has not been studied in pediatric patients.

Orencia should not be administered concomitantly with TNF antagonists.

Orencia is not recommended for use concomitantly with other biologic rheumatoid arthritis (RA) therapy, such as anakinra.

Orencia is intended for use under the guidance of a physician or healthcare practitioner.

Indication/Usage and Important Safety Information for ORENCIA ® (abatacept)


Adult Rheumatoid Arthritis (RA): ORENCIA ® (abatacept) is a prescription medicine that reduces signs and symptoms in adults with moderate to severe rheumatoid arthritis (RA), including those who have not been helped enough by other medicines for RA. ORENCIA may prevent further damage to your bones and joints and may help your ability to perform daily activities. In adults, ORENCIA may be used alone or with other RA treatments other than tumor necrosis factor (TNF) antagonists.

Juvenile Idiopathic Arthritis (JIA): ORENCIA also reduces signs and symptoms in children and adolescents 6 years of age and older with moderate to severe polyarticular juvenile idiopathic arthritis (JIA). ORENCIA may be used alone or with methotrexate (MTX).

Important Safety Information About ORENCIA ® (abatacept)

Inform your healthcare provider of the following, before you receive treatment with ORENCIA:

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community


Chart of I:DJI
DOW 16,521.25 -121.76 -0.73%
S&P 500 1,973.89 -14.98 -0.75%
NASDAQ 4,784.9430 -43.3820 -0.90%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs